New European Leadership Backpedals: EU Device Oversight Will Stay In Health Division
This article was originally published in The Gray Sheet
The incoming president of the European Commission has reversed a decision that would have moved EU oversight of medical device and drug policy issues from the health division to the markets/industry division following criticism from lawmakers and health care advocates.
You may also be interested in...
At the end of the Brexit transition period, the UK will be charting its own course through the often choppy seas of medicines regulation. While it plans to retain the existing EU rules that have been transposed into domestic legislation, it also wants the freedom to tailor its regulations in areas like clinical trials, advanced therapies and product labeling.
Health technology assessment body NICE is consulting on draft guidance that recommends Axonics' device for overactive bladder.